Condition: Tuberculosis, Pulmonary · Sponsor: Huashan Hospital
Tuberculosis (TB) remains the most important infectious disease in the world. A major barrier to tuberculosis control is poor adherence to long-term and complex treatment regimens. This is a multicenter prospective, non-inferiority randomized controlled study. The purpose of our study is a) to evaluate the tolerability, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of the high-dose rifapentine, b) to evaluate whether the high-dose rifapentine-containing regimen has the potential to treat the rifampicin-sensitive pulmonary tuberculosis and shorten the course of treatment to 17 weeks. This study is of great significance for shortening the course of treatment, reducing the adverse reactions and economic burden of patients' treatment in rifampicin-sensitive tuberculosis patient.
This description comes directly from the study's public registry record.
Feng Sun, Dr. · (086)15921403893 · aaronsf1125@126.com
Yang Li, Dr. · (086)18817583793 · y_li11@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Guiyang Public Health Clinical Center | Guiyang, Guizhou, China | Not Yet Recruiting |
| People's Hospital of Qiandongnan | Kaili, Guizhou, China | Not Yet Recruiting |
| The Third People's Hospital of Liupanshui | Liupanshui, Guizhou, China | Not Yet Recruiting |
| Affiliated Hospital of Zunyi Medical University | Zunyi, Guizhou, China | Not Yet Recruiting |
| Department of Infectious Disease, Huashan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| People's Hospital of Zhuji, Zhejiang Province | Zhuji, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05401071